EUVIMEDEUVIMED entdecken
Crossref

Interleukin‐17A modulates retinal inflammation by regulating microglial activation via the p38 MAPK pathway in experimental glaucoma neuropathy

Junjue Chen, Huimin Zhong, Huan Yu iD, Jun Sun, Bingqiao Shen, Xing Xu iD, Shouyue Huang, Ping Huang, Yisheng Zhong iD

The FASEB Journal · 2023

DOI: 10.1096/fj.202202056rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Junjue Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Ruijin Hospital Affiliated Medical School, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Glaucoma, Ocular Hypertension. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a prototypical member of the IL‐17 family, interleukin‐17A (IL‐17A) has received increasing attentions for its potent proinflammatory role as well as potential to be a key therapeutic target in human autoimmune inflammatory diseases; however, its roles in other pathological scenarios like neuroinflammations are not fully elucidated yet but appear essentially correlating and promising. Glaucoma is the leading cause of irreversible blindness with complicated pathogenesis still to be understood, where neuroinflammation was reported to be critically involved in its both initiation and progression. Whether IL‐17A takes part in the pathogenesis of glaucoma through interfering neuroinflammation due to its potent proinflammatory effect is still unknown. In the present study, we investigated the role of IL‐17A in the pathological process of glaucoma neuropathy as well as its relationship with the predominant immune inflammation mediator microglia in retina, trying to elucidate the underlying mechanisms from the view of inflammation modulation. In our study, RNA sequencing was performed for the retinas of chronic ocular hypertension (COH) and control mice. Western blot, RT‐PCR, immunofluorescence, and ELISA were used to evaluate the microglial activation and proinflammatory cytokines release at conditioned levels of IL‐17A, along with assessment of optic nerve integrity including retinal ganglion cells (RGCs) counting, axonal neurofilament quantification, and flash visual‐evoked potential (F‐VEP) examination. And the possibly involved signaling pathways were screened out to go through further validation in scenarios with conditioned IL‐17A. Subsequently, IL‐17A was found to be significantly upregulated in COH retina. Furthermore, suppression of IL‐17A effectively diminished the loss of RGCs, improved axonal quality, and F‐VEP performance in COH mice. Mechanistically, IL‐17A promoted microglial activation and proinflammatory cytokines release along with enhanced phenotypic conversion of activated microglia to M2‐type in early stage and to M1‐type in late stage in glaucomatous retinas. Microglia elimination decreased the proinflammatory factors secretion, enhanced the RGCs survival and axonal quality mediated by IL‐17A. Furthermore, IL‐17A‐induced the overactivation of microglia in glaucomatous condition was alleviated after blocking the p38 MAPK pathway. Taken together, IL‐17A is involved in the regulation of retinal immune response and RGCs cell death in experimental glaucoma by essentially promoting retinal microglial activation via p38 MAPK signaling pathway. IL‐17A dynamically regulates the phenotypic conversion of retinal microglia in experimental glaucoma partly depending on the duration of elevated intraocular pressure. Suppression of IL‐17A contributes to alleviate glaucoma neuropathy and exhibits promising potential as an innovative target for therapeutic strategy in glaucoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlaucomaOcular HypertensionMiceHumansAnimalsInterleukin-17Microgliap38 Mitogen-Activated Protein KinasesNeuroinflammatory DiseasesRetinaInflammationCytokinesDisease Models, Animal

Stichwörter der Autor:innen

experimental glaucomainterleukin-17Amicroglianeuroinflammationp38 MAPK signaling pathway

Substanzen

Interleukin-17p38 Mitogen-Activated Protein KinasesCytokines

Autor:innen und Institutionen

  • Department of Ophthalmology, Ruijin Hospital Affiliated Medical School, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shanghai Key Laboratory for Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital Affiliated Medical School, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Ophthalmology, Zhoushan Branch of Ruijin Hospital Affiliated Medical School, Shanghai Jiao Tong University, Zhoushan, China.

ORCID-Profile: Huan Yu, Xing Xu, Yisheng Zhong

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, J., Zhong, H., Yu, H., Sun, J., Shen, B., Xu, X., Huang, S., Huang, P., & Zhong, Y. (2023). Interleukin‐17A modulates retinal inflammation by regulating microglial activation via the p38 MAPK pathway in experimental glaucoma neuropathy. The FASEB Journal. https://doi.org/10.1096/fj.202202056rr

Vancouver

Chen J, Zhong H, Yu H, Sun J, Shen B, Xu X, et al. Interleukin‐17A modulates retinal inflammation by regulating microglial activation via the p38 MAPK pathway in experimental glaucoma neuropathy. The FASEB Journal. 2023. doi:10.1096/fj.202202056rr

BibTeX
@article{Chen2023,
  author = {Chen, Junjue and Zhong, Huimin and Yu, Huan and Sun, Jun and Shen, Bingqiao and Xu, Xing and Huang, Shouyue and Huang, Ping and Zhong, Yisheng},
  title = {Interleukin‐17A modulates retinal inflammation by regulating microglial activation via the p38 MAPK pathway in experimental glaucoma neuropathy},
  journal = {The FASEB Journal},
  year = {2023},
  doi = {10.1096/fj.202202056rr}
}
Kostenlos starten →